Strata Critical Medical Inc

Strata Critical Medical Inc (SRTA) Stock Analysis

$4.730

+0.040 (+0.85%)At close

Loading chart…
High
4.790
Open
4.700
VWAP
4.72
Volume
724.52K
Mkt Cap
—
Low
4.650
Amount
3.42M
EV/EBITDA, TTM
-93.20

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient.

AI analysis of Strata Critical Medical Inc (SRTA)

Buy

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report, which showed a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and a gross margin of 26.1%. Additionally, the stock is currently priced at $4.54, which is below its Fibonacci resistance levels, suggesting potential for upward movement. However, the forward P/E ratio is notably high at 138.89, indicating that the stock may be overvalued if growth does not materialize as expected.

Valuation Metrics

The current forward P/E ratio for Strata Critical Medical Inc (SRTA) is 138.89, compared to its 5-year average forward P/E of 69.75.

Forward P/E

Fair
5Y Average P/E
69.75
Current P/E
138.89
Overvalued
148.88
Undervalued
-9.39

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
92.03
Current EV/EBITDA
-93.20
Overvalued
350.85
Undervalued
-166.80

Forward P/S

Fair
5Y Average P/S
1.41
Current P/S
1.27
Overvalued
1.64
Undervalued
1.18

Whales holding SRTA

T

Third Point LLC

+ HoldingSRTA

-2.85%

3M Return

Events Timeline

2026-05-06 (ET)

07:40:00

Strata Adjusts FY26 EBITDA Guidance to $29M-$33M

07:40:00

Company Reports Q1 Revenue of $67.38M, Exceeding Expectations

2026-03-03 (ET)

07:10:00

Raises EBITDA Outlook to $29M-$33M

07:10:00

Will Heyburn: Company Aims for 30% Annual EBITDA Growth

2026-02-05 (ET)

08:50:00

Strata Critical Medical Enters $30M Credit Agreement with JPMorgan

News

SRTA FAQ — answered by Alphio AI

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. It operates in the Industrials sector.

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report, which showed a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and a gross margin of 26.1%. Additionally, the stock is currently priced at $4.54, which is below its Fibonacci resistance levels, suggesting potential for upward movement. However, the forward P/E ratio is notably high at 138.89, indicating that the stock may be overvalued if growth does not materialize as expected.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading